161 related articles for article (PubMed ID: 38716401)
1. Three-years of dalbavancin use at a UK tertiary referral hospital serving a population with high numbers of people who inject drugs.
Bresges C; Bresges K; Hewitt C; Sharma S; Davies B
JAC Antimicrob Resist; 2024 Jun; 6(3):dlae066. PubMed ID: 38716401
[TBL] [Abstract][Full Text] [Related]
2. Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections.
Bork JT; Heil EL; Berry S; Lopes E; Davé R; Gilliam BL; Amoroso A
Infect Dis Ther; 2019 Jun; 8(2):171-184. PubMed ID: 31054088
[TBL] [Abstract][Full Text] [Related]
3. Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs.
Gonzalez PL; Rappo U; Akinapelli K; McGregor JS; Puttagunta S; Dunne MW
Drugs Context; 2018; 7():212559. PubMed ID: 30574170
[TBL] [Abstract][Full Text] [Related]
4. Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care.
Ajaka L; Heil E; Schmalzle S
Antibiotics (Basel); 2020 Oct; 9(10):. PubMed ID: 33076275
[TBL] [Abstract][Full Text] [Related]
5. Use of dalbavancin in infective endocarditis: a case series.
Guleri A; More R; Sharma R; Wong M; Abdelrahman A
JAC Antimicrob Resist; 2021 Sep; 3(3):dlab099. PubMed ID: 34396119
[TBL] [Abstract][Full Text] [Related]
6. Substance use disorder-associated infections' treatment with dalbavancin enabling outpatient transition (SUDDEN OUT) - an investigator-initiated single-arm unblinded prospective cohort study.
Krsak M; Scherger S; Miller MA; Cobb V; Montague BT; Henao-Martínez AF; Molina KC
Ther Adv Infect Dis; 2024; 11():20499361231223889. PubMed ID: 38249543
[TBL] [Abstract][Full Text] [Related]
7. Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study.
Rebold N; Alosaimy S; Pearson JC; Dionne B; Taqi A; Lagnf A; Lucas K; Biagi M; Lombardo N; Eudy J; Anderson DT; Mahoney MV; Kufel WD; D'Antonio JA; Jones BM; Frens JJ; Baumeister T; Geriak M; Sakoulas G; Farmakiotis D; Delaportas D; Larew J; Veve MP; Rybak MJ
Infect Dis Ther; 2024 Mar; 13(3):565-579. PubMed ID: 38427289
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital.
Lueking R; Wei W; Mang NS; Ortwine JK; Meisner J
Microbiol Spectr; 2023 Feb; 11(1):e0238522. PubMed ID: 36537818
[TBL] [Abstract][Full Text] [Related]
9. French national cohort of first use of dalbavancin: A high proportion of off-label use.
Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
[TBL] [Abstract][Full Text] [Related]
10. Risk of New Bloodstream Infections and Mortality Among People Who Inject Drugs With Infective Endocarditis.
Tan C; Shojaei E; Wiener J; Shah M; Koivu S; Silverman M
JAMA Netw Open; 2020 Aug; 3(8):e2012974. PubMed ID: 32785635
[TBL] [Abstract][Full Text] [Related]
11. Dalbavancin as an alternative to traditional outpatient parenteral antimicrobial therapy for deep gram-positive infections - an observational, retrospective review.
Bao H; Igwilo-Alaneme R; Sonia F; Cowman K; Kahn M; Nori P
Ther Adv Infect Dis; 2024; 11():20499361241245523. PubMed ID: 38645297
[TBL] [Abstract][Full Text] [Related]
12. Real-World Use of Dalbavancin for Treatment of Soft Tissue and Bone Infection in Children: Safe, Effective and Hospital-Time Sparing.
Caselli D; Mariani M; Colomba C; Ferrecchi C; Cafagno C; Trotta D; Carloni I; Dibello D; Castagnola E; Aricò M
Children (Basel); 2024 Jan; 11(1):. PubMed ID: 38255391
[TBL] [Abstract][Full Text] [Related]
13. Real-World Dalbavancin Use for Serious Gram-Positive Infections: Comparing Outcomes Between People Who Use and Do Not Use Drugs.
Zambrano S; Paras ML; Suzuki J; Pearson JC; Dionne B; Schrager H; Mallada J; Szpak V; Fairbank-Haynes K; Kalter M; Prostko S; Solomon DA
Open Forum Infect Dis; 2024 Apr; 11(4):ofae186. PubMed ID: 38651139
[TBL] [Abstract][Full Text] [Related]
14. Recurrent Endocarditis in Persons Who Inject Drugs.
Rodger L; Shah M; Shojaei E; Hosseini S; Koivu S; Silverman M
Open Forum Infect Dis; 2019 Oct; 6(10):ofz396. PubMed ID: 31660358
[TBL] [Abstract][Full Text] [Related]
15. The burden of skin and soft tissue, bone and joint infections in an Australian cohort of people who inject drugs.
Morgan B; Lancaster R; Boyagoda B; Ananda R; Attwood LO; Jacka D; Woolley I
BMC Infect Dis; 2024 Mar; 24(1):299. PubMed ID: 38454356
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact and public health challenges of a PVL-MRSA bacteraemia outbreak amongst people who inject drugs in South Yorkshire, UK.
Beaumont M; Subramanian B; Agwuh K; Ryan Y; Pichon B
Access Microbiol; 2024; 6(2):. PubMed ID: 38482361
[TBL] [Abstract][Full Text] [Related]
17. Dalbavancin as sequential therapy in infective endocarditis: Real-life experience in elder and comorbid patients.
Aparicio-Minguijón E; Boán J; Terrón A; Heredia C; Puente C; Pérez-Jacoiste Asín A; Orellana MÁ; Domínguez L; Caro JM; López-Gude MJ; Aguilar-Blanco EM; Eixerés-Esteve A; López-Medrano F
Enferm Infecc Microbiol Clin (Engl Ed); 2024 Jun; ():. PubMed ID: 38902152
[TBL] [Abstract][Full Text] [Related]
18. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.
Steele JM; Seabury RW; Hale CM; Mogle BT
J Clin Pharm Ther; 2018 Feb; 43(1):101-103. PubMed ID: 28628223
[TBL] [Abstract][Full Text] [Related]
19. Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant
Mazzitelli M; Gatti M; Scaglione V; Mengato D; Trevenzoli M; Sattin A; Pea F; Cattelan AM
Antibiotics (Basel); 2022 Oct; 11(10):. PubMed ID: 36290035
[TBL] [Abstract][Full Text] [Related]
20. REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.
Papavramidis T; Gentile I; Cattelan AM; Magnasco L; Viale P; Francisci D; Kofteridis DP; Tiseo G; Giamarellos-Bourboulis EJ; Lagi F; Pinna SM; D'Amico F; La Ferla L; Panagopoulos P; Gattuso G; Sipsas NV; Ruggieri A; Cattaneo A; Corio L; Comandini A; Mascagni P; Bassetti M
Int J Antimicrob Agents; 2023 Apr; 61(4):106746. PubMed ID: 36758778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]